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ageing human subjects. The inability to accumulate the right type of extracellular matrix components may 
be regarded as a failure of intrinsic repair by articular cartilage cells. Increased coagulant activity in 
subchondral bone of OA patients can explain the venous congestion occurring in OA subchondral bone. This 
venous congestion causes pain and malnutrition of the subchondral tissue. 
Some oversulphated polysaccharides are known to stimulate the synthesis and to inhibit catabolism of 
extracellular matrix components and therefore, are believed to protect articular cartilage in OA. Amongst 
these polysaccharides, calcium pentosan polysulphate (CaPPS) was shown to increase IL-6 production and 
proteoglycan (aggrecan) synthesis of chondrocytes cultured in agarose. Aggrecan aggregate molecular sizes 
was significantly increased in the presence of CaPPS. This effect was largely due to an increase in the length 
of the hyaluronan backbone, to which larger numbers of aggrecan monomer units could be attached. In vivo, 
intra-articular dministration ofCaPPS was also shown to increase hyaluronan chain length in synovial fluid 
of patients with inflammatory joint diseases. These oversulphated polysaccharides also have anti-coagulant 
effects and are known to enhance fibrinolytic activity in blood. Therefore, they may improve microcirculation 
in subchondral bone. 
The pleiotropic effects on connective tissue cells o~ these oversulphated polysaccharides m~y be explained 
by an interference with a key-factor in the regulation of connective tissue metabolism. Therefore, studies 
were undertaken i order to identify serological parameters which could correlate with the pathology of OA 
and/or with clinical improvement following therapy. 
Twenty-three patients uffering from OA of the hips, knees or fingerjoints were given five injections of C aPPS 
(2 mg/kg; once weekly) subcutaneously. Their clinical symptoms were recorded at start and during a 16-week 
period. Plasma coagulant and fibrinolytic activity were assayed at the start and after 1, 2,~4, 8, 24 hours of 
the first injection. These parameters were complemented with liver, kidney function and lipid assays and 
peripheral blood cell counts during each clinical visit. These studies howed that pain scores and functional 
indices improved significantly after 3-4 injections in patients with OA of knee and fingerjoints. Coagulant 
activities were significantly decreased 2-4 hours after administration. Statistically significant increases in 
serum fibrinolytic activity were recorded 24 hours after one CaPPS injection [tPA (tissue pl'asminogen 
activator activity) increased after 8 and 24 hours and (PAI) plasminogen activator inhibitor activity 
decreased after 4 and 8 hours and continued to decrease 12 weeks after the fifth injection]. Raised plasma 
alpha-anti-trypsin inhibitor activities may have correlated with decreased elastase activities and hence with 
decreased potential for destruction of connective tissues. An increase in acute-phase r sponse in PPS-treated 
patients may be the consequence ofa stimulation of IL-6-release (in vitro finding) by their connective tissue 
cells. 
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In t roduct ion  
At present patients with OA and their response to drug treatments are usually followed longitudinally using 
clinical and/or radiological methods of assessment. While several validated methods of measuring clinical 
outcomes in OA patients have been described [1], none provides a sensitive index of the pathological status 
of the disease. Molecular markers of cartilage and bone turnover have been quantitated in patient's ynovial 
fluid (SF) or sera and have shown correlations with radiological grading of hard tissue pathology [2] [3]. 
However, to date these markers have not been correlated with clinical symptoms or used to monitor the 
response of OA patients to disease modifying drug therapies. We have previously proposed that the 
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measurement of monocyte procoagulant activity (MPA) after challenge with cartilage-derived antigens in 
OA patients might provide such a marker [4]. 
Therapies currently available for the treatment of OA, for the most part, only modify the symptoms of the 
disease rather than the underlying cause. From laboratory studies [5] and our previous clinical investigations 
[6], we considered that pentosan polysulphate (PPS) offered potential as an agent with disease modifying 
activities in OA. The objective of the present investigation was to evaluate this hypothesis. 
Methods  and Resu l ts  
In this study the effects of 4 weekly intramuscular injections of PPS (3 mg/kg) were determined on OA patients 
(n= 11) symptoms, peripheral blood monocyte procoagulant activity (MPA) [7] and blood white cell 
populations over an initial 24 h period and then 8 weeks thereafter. Clinical assessment continued for weeks 
12, 16, 20 and 24 from initiation of the study. In all patients MPA was reduced relative to baseline pre-drug 
values for up to 24 h post-PPS treatment. In those patients with a moderate, but not mild, grade of OA this 
reduction in MPA was sustained for up to 4 weeks fol lowingthe last (4th) i.m. injection of PPS. The reduction 
in patient's MPA correlated for the moderate OA group, with a decline in many of their clinical symptoms 
including: global pain (r = 0.958), effectiveness of treatment (r = 0.915), pain on walking (r = 0.800) and time 
to climb 15 steps (r = 0.768). The precentage of leucocytes increased in blood of all OA patients receiving PPS, 
maximum levels being achieved after 8 h. The major contribution to this rise in leucocytes was from 
lymphocytes since monocytes and neutrophils actually decreased after PPS treatment. Significantly, 4weeks 
after the last PPS injection the lymphocyte populations were still elevated (p < 0.04) and neutrophils 
depressed (p < 0.04) in the blood 8 of the 11 patients tudied. Platelet levels were also elevated in PPS-treated 
patients relative to their baseline values (p < 0.005). 
Conc lus ion 
The present findings leads us to conclude that monocyte procoagulant activity could provide a useful means 
of monitoring disease progression and patients response to disease modifying drug treatments in OA. This 
study also demonstrated that PPS altered the distribution of leucocytes present in blood of OA patients. Most 
notable was the elevation of the percentage of lymphocytes present and the depression of neutrophil evels 
for up to 4 weeks after the last injection of the drug. Although numbers were small, in those OA patients 
whose lymphocytes and neutrophils levels returned to their baseline values, symptoms re-appeared. From 
these investigations, we conclude that PPS is a drug with an unusual mechanism of action. Apart from its 
known pleotropic actions on connective tissues and epithelium, it now appears that it is also 
immunoregulatory both in terms of leucocyte recruitment and in the expression by these cells of activities 
which are implicated in the pathogenesis of OA. 
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The aim of this paper is to present some of the questions that need to be addressed before interpreting current 
data and conducting future trials and evaluation of intra-articular therapies for asteoarthritis (OA), Patient 
selection, disease subsets, outcome measures, trial setting, symptoms control, drop-outs and placebo response 
will be discussed. 
